PL3352735T3 - Formulacje olanzapiny o przedłużonym uwalnianiu - Google Patents

Formulacje olanzapiny o przedłużonym uwalnianiu

Info

Publication number
PL3352735T3
PL3352735T3 PL16775424.1T PL16775424T PL3352735T3 PL 3352735 T3 PL3352735 T3 PL 3352735T3 PL 16775424 T PL16775424 T PL 16775424T PL 3352735 T3 PL3352735 T3 PL 3352735T3
Authority
PL
Poland
Prior art keywords
sustained release
olanzapine formulations
release olanzapine
formulations
sustained
Prior art date
Application number
PL16775424.1T
Other languages
English (en)
Inventor
Mark Alan Smith
Carine CLAASSEN-PUNT
Original Assignee
Teva Pharmaceuticals International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International Gmbh filed Critical Teva Pharmaceuticals International Gmbh
Publication of PL3352735T3 publication Critical patent/PL3352735T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)
PL16775424.1T 2015-09-21 2016-09-21 Formulacje olanzapiny o przedłużonym uwalnianiu PL3352735T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
PL3352735T3 true PL3352735T3 (pl) 2024-01-29

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16775424.1T PL3352735T3 (pl) 2015-09-21 2016-09-21 Formulacje olanzapiny o przedłużonym uwalnianiu

Country Status (21)

Country Link
US (4) US20170079985A1 (pl)
EP (2) EP3352735B1 (pl)
JP (2) JP2018527397A (pl)
KR (1) KR20180054627A (pl)
CN (2) CN108289834A (pl)
AR (1) AR106085A1 (pl)
AU (2) AU2016328958B2 (pl)
CA (1) CA2998504C (pl)
CL (1) CL2018000727A1 (pl)
DK (1) DK3352735T3 (pl)
EA (1) EA201890788A1 (pl)
ES (1) ES2960753T3 (pl)
FI (1) FI3352735T3 (pl)
HU (1) HUE063850T2 (pl)
IL (3) IL295161A (pl)
MX (2) MX2018003380A (pl)
NZ (1) NZ740665A (pl)
PL (1) PL3352735T3 (pl)
PT (1) PT3352735T (pl)
TW (1) TWI798161B (pl)
WO (1) WO2017053346A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172850A1 (en) * 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
BR112020013750A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
PH12022550775A1 (en) * 2019-12-20 2023-08-23 Alar Pharmaceuticals Inc Long-acting injectable formulations of ketamine pamoate salts
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
JP2026501805A (ja) * 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6169084B1 (en) * 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CA2615173C (en) * 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
US8206735B2 (en) 2006-07-11 2012-06-26 Foresee Pharmaceuticals, Llc Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
WO2009148580A2 (en) 2008-06-03 2009-12-10 Qlt Usa, Inc. Controlled release copolymer formulation with improved release kinetics
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
PL2394663T3 (pl) * 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
HRP20192276T1 (hr) 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
US20130144250A1 (en) 2011-10-24 2013-06-06 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
BR112014017969A8 (pt) 2012-01-23 2017-07-11 Allergan Inc Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
US9943484B2 (en) 2013-06-20 2018-04-17 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
KR20180054627A (ko) 2018-05-24
US20220323458A1 (en) 2022-10-13
AU2022206695A1 (en) 2022-08-11
ES2960753T3 (es) 2024-03-06
EA201890788A1 (ru) 2018-09-28
HK1255946A1 (en) 2019-09-06
JP2021167331A (ja) 2021-10-21
CN108289834A (zh) 2018-07-17
FI3352735T3 (fi) 2023-10-20
AU2016328958A1 (en) 2018-04-05
CN116942677A (zh) 2023-10-27
TWI798161B (zh) 2023-04-11
US20180264001A1 (en) 2018-09-20
AR106085A1 (es) 2017-12-13
CA2998504A1 (en) 2017-03-30
CL2018000727A1 (es) 2018-09-28
WO2017053346A1 (en) 2017-03-30
IL258086A (en) 2018-05-31
IL295161A (en) 2022-09-01
CA2998504C (en) 2023-06-20
EP3352735A1 (en) 2018-08-01
PT3352735T (pt) 2023-10-30
NZ740665A (en) 2023-04-28
MX2022007315A (es) 2022-07-13
MX2018003380A (es) 2018-08-16
AU2016328958B2 (en) 2022-04-21
HUE063850T2 (hu) 2024-02-28
US20240238307A1 (en) 2024-07-18
EP3352735B1 (en) 2023-08-30
IL275735A (en) 2020-08-31
JP2018527397A (ja) 2018-09-20
US20170079985A1 (en) 2017-03-23
EP4331570A1 (en) 2024-03-06
TW201726144A (zh) 2017-08-01
DK3352735T3 (da) 2023-10-30

Similar Documents

Publication Publication Date Title
PL4070787T3 (pl) Formulacje farmaceutyczne
IL265609A (en) New formulations
IL256491A (en) Pharmaceutical formulations
GB201404139D0 (en) Sustained release buprenorphine solution formulations
GB201607918D0 (en) Novel formulations
IL275735A (en) Olanzapine sustained release pharmaceutical preparation
GB201516554D0 (en) Controlled-release formulations
PL3364945T3 (pl) Stały preparat
GB201419091D0 (en) Formulations
ZA201704263B (en) Controlled-release formulations
GB201419261D0 (en) Formulations
AU366777S (en) Pessary
SG11201803156TA (en) Sustained release formulations of local anesthetics
IL254794A0 (en) Pharmaceutical formulations
IL254159A0 (en) Stimulant formulations with triple release
IL269403A (en) Olanzapine sustained release pharmaceutical preparation
IL247828A0 (en) Progesterone compounds
GB201504482D0 (en) Novel formulations
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201513140D0 (en) Release me